EANS-News: Balda AG / Medical subsidiary obtains regulatory approval for an innovative product under its own name for the first time

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

New Products

Bad Oeynhausen (euro adhoc) - Balda AG: Medical subsidiary obtains
regulatory approval for an innovative product under its own name for
the first time

Successful system integration of hardware and software for a unique
pharmaceutical dispenser

Bad Oeynhausen, 6 October 2010 - Balda Medical GmbH & Co. KG, Bad
Oeynhausen, an affiliated company of Balda AG listed on the SDax on
the Frankfurt Stock Exchange, has successfully completed the
development of an innovative product on behalf of a global
pharmaceutical client. "The device supports the effect of the
medicine by timely, precise and regular use. This unique
pharmaceutical dispenser combines both mechanical components and
electronic assistance systems in one. We are responsible for both,
the complete implementation of hardware as well as software",
explains Dr. Rolf Eilers, CEO of Balda Medical. In addition, the
company satisfies all regulatory requirements. Balda Medical has
obtained the regulatory approval for the pharmaceutical dispenser
under its own name for the first time for the European market
(CE-symbol). The core business of the company, based in Bad
Oeynhausen, comprises the development, the set up for mass production
and the production of disposable articles as well as complex products
manufactured from plastic. The main customer base comes from the
pharmaceuticals, diagnostics and medical technology market segments.

The product, which is also intended for the U.S. market, was
developed in accordance with the requirements of the U.S. Food and
Drug Administration (FDA). Balda Medical will provide comprehensive
product documentation for the approval procedure, called "Device
Master File". The company has been registered as a manufacturer by
the FDA since 2009.

With the new drug dispenser Balda Medical is following important
market trends in two ways. The rapidly increasing self-care of
patients with hand-held devices occurs more frequently now using
electronic support. The appropriate and controlled intake of medicine
allows for a significantly improved treatment of patients.

The successful system integration of software and hardware, as well
as the lead responsibility for regulatory requirements, demonstrates
the broad service portfolio and the competitive strengths of the
system partner Balda Medical. "The demand from our customers for a
variety of capabilities from one source is constantly increasing,"
said Eilers.

* * * Company Profile Balda AG The Balda Group develops and produces
complete plastic assemblies, electronic products and products for the
medical industry. The customers of Balda are leaders in business from
the mobile, entertainment and electronic communications as well as
pharmaceutical and medical technology markets. The group has an
international position with product sites in China, Malaysia and
Germany. A subsidiary in the United States serves North American
customers in product design and development. As part of a
shareholding in a leading manufacturer of touch screens in China,
Balda participates in the dynamic touch screen displays market.

* * *

This corporate news announcement includes "forward-looking
statements" which are based on the current expectations of the
management of Balda. They are subject to risks and uncertainty
because they relate to events and depend on circumstances that will
occur in the future, such as, for example, developments in the mobile
communications industry, changes in technology and the ability to
timely and successfully develop new products and various other
factors. Balda does not undertake any obligation to update publicly
or revise forward-looking statements except to the extent legally
required. This corporate news announcement is not an offer of
securities for sale or a solicitation of an offer to purchase
securities in the United States or elsewhere. The shares in Balda AG
(the "Shares") may not be offered or sold in the United States or to
or for the account or benefit of U.S. persons (as such term is
defined in Regulation S under the U.S. Securities Act of 1933, as
amended (the "Securities Act") unless registered under the Securities
Act or pursuant to an exemption from such registration. The Shares
have not been and will not be registered under the Securities Act.

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: Balda AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Clas Röhl

Tel.: +49 (0) 5734 922-2728

croehl@balda.de

Branche: Semiconductors & active components
ISIN: DE0005215107
WKN: 521510
Index: CDAX, Prime All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Hamburg / free trade
Stuttgart / free trade
Düsseldorf / free trade
München / free trade